Sign in
ELUT Stock Price, Chart, Stats & News
Elutia Inc
Save
43.37M
Market cap
–
Current P/E
–
Forward P/E
ELUT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 49.14% |
Operating margin | -150.88% |
Pretax margin | -108.13% |
Net margin | 282.63% |
Effective tax rate | -0.06% |
ROA | 85.61% |
ROE | -225.83% |
D/E | 0.40x |
Interest coverage ratio | 73.63x |
ELUT valuation
P/E | – |
P/S | 2.42x |
P/B | 1.65x |
P/CF | – |
P/FCF | -32.38x |
P/OCF | – |
PEG | 0.00x |
EV multiple | -5.38x |
About
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
Similar securities
Based on sector and market capitalization
Report issue